Quick Answer
Petros Pharmaceuticals, Inc. reported Diluted EPS of $3.34 per share (loss) for fiscal year 2024.
Petros Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$3.34 | +47.4% |
| 2023 | -$6.35 | +34.4% |
| 2022 | -$9.68 | -17.3% |
| 2021 | -$8.25 | -114.3% |
| 2020 | -$3.85 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.03 | +99.8% | +97.7% |
| June 30, 2025 | -$1.29 | +86.1% | +86.2% |
| March 31, 2025 | -$9.37 | +77.8% | +43.7% |
| September 30, 2024 | -$16.65 | -484.2% | -80.0% |
| June 30, 2024 | -$9.25 | -670.8% | +78.1% |
| March 31, 2024 | -$42.19 | -6292.4% | -1380.4% |
| September 30, 2023 | -$2.85 | +57.4% | -137.5% |
| June 30, 2023 | -$1.20 | -36.4% | -81.8% |
- Petros Pharmaceuticals, Inc. showed an increase of +47.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Petros Pharmaceuticals, Inc.’s diluted eps has grown by 13.2% (from $3.85 per share (loss) to $3.34 per share (loss)).
- The most recent figure is from Petros Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: